These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 25955657

  • 1. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A, Bystrup S, Ruiz de Porras V, Guardia C, Musulén E, Martínez-Cardús A, Manzano JL, Layos L, Abad A, Martínez-Balibrea E.
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [Abstract] [Full Text] [Related]

  • 2. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
    Lu WQ, Hu YY, Lin XP, Fan W.
    Oncotarget; 2017 Jul 04; 8(27):44171-44185. PubMed ID: 28498807
    [Abstract] [Full Text] [Related]

  • 3. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
    Li Q, Zhang D, Chen X, He L, Li T, Xu X, Li M.
    Sci Rep; 2015 Nov 06; 5():16082. PubMed ID: 26542452
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ, Lin HY, Zhang Y, Chen WF.
    J Gene Med; 2020 Jul 06; 22(7):e3178. PubMed ID: 32092782
    [Abstract] [Full Text] [Related]

  • 8. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A, Matthes N, Mühling B, Koospal M, Quenzer A, Peter S, Germer CT, Linnebacher M, Otto C.
    Neoplasia; 2017 Apr 06; 19(4):301-309. PubMed ID: 28284059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC.
    Oncogene; 2008 Jul 10; 27(30):4161-71. PubMed ID: 18345033
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Bommer UA, Vine KL, Puri P, Engel M, Belfiore L, Fildes K, Batterham M, Lochhead A, Aghmesheh M.
    Cell Commun Signal; 2017 Feb 01; 15(1):9. PubMed ID: 28143584
    [Abstract] [Full Text] [Related]

  • 13. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells.
    Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N.
    Int J Oncol; 2006 Jul 01; 29(1):225-35. PubMed ID: 16773204
    [Abstract] [Full Text] [Related]

  • 14. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R, Yin J, Zhang Y, Zhang S.
    J Cell Biochem; 2019 Sep 01; 120(9):14585-14593. PubMed ID: 30998268
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.